Valuation: NetraMark Holdings Inc.

Market Cap 6.59Cr 4.67Cr 4.1Cr 3.82Cr 3.51Cr 447.5Cr 6.67Cr 45Cr 18Cr 220.97Cr 18Cr 17Cr 763.74Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.59Cr 4.67Cr 4.1Cr 3.82Cr 3.51Cr 447.5Cr 6.67Cr 45Cr 18Cr 220.97Cr 18Cr 17Cr 763.74Cr EV / Sales 2026 *
164x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
09/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
29/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
09/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
25/03 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
25/03 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
25/03 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
1 day-8.97%
1 week-11.25%
Current month+12.70%
1 month+14.52%
3 months-24.47%
6 months-36.04%
Current year-35.45%
1 week 0.69
Extreme 0.69
0.79
1 month 0.59
Extreme 0.59
0.95
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
2.25
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Option

Chief Financial Officer

18,750 0.0202%
26/06/26 Option

Chief Financial Officer

-18,750 0.0202%
25/06/26 Option

Chief Executive Officer

4,49,375 0.4845%
Change 5-day change 1-year change 3-year change Capi.($)
-8.97%-11.25%-51.03%+173.08% 5.14Cr
+1.94%-3.28%-24.26%+17.65% 2,83500Cr
+7.00%-2.46%-17.17%+714.43% 29TCr
+1.31%+2.65%+174.64%+1,019.73% 11TCr
+3.79%+2.63%+1.93%+44.15% 9TCr
+2.03%-4.31%+68.09%+130.09% 8.79TCr
+4.16%+2.78%-35.34%-13.32% 7.15TCr
+4.39%-1.23%-33.81%+73.26% 6.12TCr
+5.31%+2.08%+8.54%+62.80% 4.3TCr
+1.83%-9.07%-59.25%+27.72% 3.4TCr
Average +0.83%-4.09%+3.23%+224.96% 36.31TCr
Weighted average by Cap. -0.38%-3.71%-14.89%+109.89%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.72Cr 4L 27.63L 10.79L 1.35Cr 10.67L 10.44L 4.65Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
27/26/27 CA$0.7100 -8.97% 62,784
24/26/24 CA$0.7800 +4.00% 5,500
23/26/23 CA$0.7500 -5.06% 2,000
22/26/22 CA$0.7900 -1.25% 25,740
21/26/21 CA$0.8000 0.00% 3,150

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock